Physician profile
Marc E Brockman
NPI 1598764672
$6,471.87
in general payments reported to CMS, 2019-2025
30 companies · $670 in 2025
The $670 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $944 · 2020: $527 · 2021: $1,038 · 2022: $1,352 · 2023: $773 · 2024: $1,169 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,611.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.43 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $713.65 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $452.86 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $400.18 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Aerie Pharmaceuticals, INC. | $384.54 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $371.07 | 2021-2024 | |
| Glaukos Corporation | $344.57 | 2024-2025 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Istent Infinite |
| Tarsus Pharmaceuticals, INC. | $288.55 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $283.54 | 2019-2020 | |
| Sight Sciences, INC. | $279.73 | 2021-2023 | Omni Surgical System |
| Kala Pharmaceuticals, INC. | $268.17 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $267.80 | 2022 | |
| Horizon Therapeutics Plc | $228.93 | 2021-2023 | Tepezza |
| Lkc Technologies, INC. | $149.45 | 2024 | |
| Oyster Point Pharma, INC. | $148.55 | 2022-2025 | Tyrvaya, Ryzumvi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $124.99 | 2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Alcon Vision LLC | $124.31 | 2022-2024 | Rocklatan |
| Beaver-Visitec International, INC. | $122.44 | 2022 | |
| Novartis Pharmaceuticals Corporation | $117.49 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.81 | 2019-2020 | |
| Biotissue Holdings INC. | $78.62 | 2019 | |
| Optos, INC. | $62.42 | 2020 | |
| Mallinckrodt Hospital Products INC. | $58.30 | 2025 | Acthar |
| Visionix USA, INC | $55.56 | 2022 | |
| Harrow Eye, LLC | $45.00 | 2025 | Vevye |
| Shire North American Group INC | $42.35 | 2019 | |
| Astellas Pharma US INC | $28.94 | 2024 | Izervay |
| Thea Pharma INC. | $24.84 | 2023 | Iyuzeh |
| Genentech USA, INC. | $21.25 | 2025 | Vabysmo |
| Amgen INC. | $20.53 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Brockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.